[1]Patent:WO2009/85983,2009,A1,.Locationinpatent:Page/Pagecolumn82
[2]Patent:WO2009/85983,2009,A1,.Locationinpatent:Page/Pagecolumn82-83
[1]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2009/85983,2009,A1Locationinpatent:Page/Pagecolumn82
[2]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2009/85983,2009,A1Locationinpatent:Page/Pagecolumn82-83
Title: Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
Journal: Bioorganic & medicinal chemistry letters 20141001
Title: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Journal: Nature 20130912
Title: MEK and the inhibitors: from bench to bedside.
Journal: Journal of hematology & oncology 20130101
Title: Hatzivassiliou G, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6.
Title: Takahashi RH, et al. Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor. Drug Metab Dispos. 2015 Dec;43(12):1929-1933.
